Gallbladder Diseases (Gall Bladder Disease)

05/01/1980 - "It is concluded that in some individuals with continuing symptoms suggesting gallbladder disease but normal oral cholecystograms, cholecystokinin cholecystography may be helpful in identifying physiologic dysfunction of the gallbladder."
01/01/1992 - "The physiologic studies on gallbladder contraction and cholecystokinin release in a subset of the patients failed to provide information on a mechanism for the possible increased incidence of gallbladder disease."
09/01/1985 - "The objective of this study was to examine the effect of aging on gallbladder contraction and cholecystokinin (CCK) release, as well as on the correlation between the two in humans who are free of gallbladder disease. "
02/01/2010 - "Calculation of a gallbladder ejection fraction after cholecystokinin infusion is commonly used to diagnose chronic acalculous gallbladder disease. "
07/01/2003 - "Acalcolous gallbladder disease is the clinical setting deserving further investigation on the value of the cholecystokinin provocative test, but this test needs to be standardized."

04/01/1987 - "This report evaluated prostaglandin E and F levels in patients with acalculous gallbladder disease. "
04/05/1975 - " It is possible that prostaglandins may also cause contraction of the human gallbladder and precipitate side effects in patients with gallbladder disease. "
11/01/1989 - "Continuing evaluation of the pathophysiology of gallbladder disease has demonstrated significant relationships between gallbladder mucosal fluid transport, gallbladder inflammation, and prostanoid formation. "
04/01/1987 - "Prostaglandins have been postulated to be involved in the formation of gallstones and the pain and inflammation of calculous gallbladder disease. "
09/01/1989 - "Cyclooxygenase inhibitors decrease gallbladder prostaglandin formation and are effective in producing relief of the symptoms of gallbladder disease. "

01/19/2005 - "Both trials showed greater risk of any gallbladder disease or surgery with estrogen (CEE: HR, 1.67; 95% CI, 1.35-2.06; E + P: HR, 1.59; 95% CI, 1.28-1.97). "
01/01/1988 - "Although an increase in the risk of gallbladder disease in women using supplemental estrogens has been consistently observed in previous studies, the risk after cessation of use has received little attention but could be important. "
07/01/1991 - "Total amount of alcohol consumed per week, number of cigarettes smoked per day, and current estrogen use were not significantly associated with gallbladder disease. "
01/01/1988 - "Our data suggest the possibility that the risk of gallbladder disease in estrogen users persists after use of the drug ceases. "
08/01/1982 - " Parous patients with gallbladder disease should be strongly encouraged to lose weight if obese, and, whether obese or not, should not be given estrogen-containing OCs."

01/01/2023 - "Our study also revealed that GS of the Lucknow region of both malignant and benign gallbladder diseases belong to the monohydrate crystalline form of cholesterol while GS of Chandigarh region of both malignant and benign gallbladder diseases exists in both monohydrate crystalline form with the amorphous type and anhydrous form. "
08/15/1987 - "These results, which need to be confirmed by further studies, show that in acalculous gallbladder disease there is a delay in gallbladder emptying which could explain the formation of cholesterol crystals by bile stasis as described by various authors."
08/01/1932 - "STUDIES IN CHOLESTEROL METABOLISM : 3. Cholesterol and Gall Bladder Disease."
12/01/2019 - "Clinicians should continue to advocate for lifestyle changes, such as maintaining a healthy weight and a diet low in fat and cholesterol, that could prevent gallbladder disease. "
09/15/2016 - "MUC Expression in Gallbladder Epithelial Tissues in Cholesterol-Associated Gallbladder Disease."

04/01/2006 - "Furthermore, agents that increase the expression of selected hepatocyte bile acid transporters may also be useful in the treatment of gall bladder disease."
08/01/2018 - "Physical activity influences the hepatobiliary-gut axis at different levels and brings benefits to fat distribution, liver fat and gallbladder disease while interacting with bile acids as signalling molecules, intestinal microbiota and inflammatory changes in the body. "
12/01/1990 - "Gallbladder disease, bile composition and bile acid absorption after partial ileal bypass."
02/01/1987 - "Bile acid concentrations were compared with 21 controls and 15 asymptomatic subjects with gall bladder disease. "
07/01/1982 - "Serum bile acids (SBA) were studied after a standard fatty meal in patients with gallbladder disease. "

07/01/2007 - "The objective of the present study was to analyse the association between (1) use of life-time MHT (ever use) and gallbladder disease and (2) nonoral use of MHT and gallbladder disease. "
07/01/2007 - "Our analyses do not lend support to the hypothesis that use of MHT is associated with gallbladder disease."
07/01/2007 - "There was no association between nonoral use of MHT and gallbladder disease. "
07/01/2007 - "We performed Poisson regression with Huber/White standard errors to investigate the association between ever use, current nonoral use of MHT and gallbladder disease. "
07/01/2007 - "We found no significant association between ever use of MHT and gallbladder disease and sonographically diagnosed gallstones in fully adjusted analyses. "

01/01/2016 - "Total protein intake was modestly protective against gallbladder disease (Ptrend<0.021). "
01/01/2016 - "This study aimed to measure associations between gallbladder disease and protein intake patterns, separated by quantity and type (vegetable vs. animal), among postmenopausal women. "
01/01/2016 - "Animal protein intake was not associated with gallbladder disease risk. "
01/01/2016 - "Cox proportional hazards regression models, adjusted for gallbladder disease risk factors, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between energy-adjusted protein intake and gallbladder disease. "
04/01/1995 - "The present research was designed to investigate the association between the polymorphisms of these proteins and the presence of various gallbladder diseases. "

11/01/2004 - "Five human studies investigated the safety and efficacy of sincalide in patients with PN-associated gallbladder disease. "
09/01/2019 - "Sincalide cholescintigraphy is most commonly used to diagnose or exclude chronic acalculous gallbladder disease. "
04/01/2006 - "For chronic acalculous gallbladder disease, calculation of a gallbladder ejection fraction during sincalide cholescintigraphy can confirm the clinical diagnosis and has become a common routine procedure in many nuclear medicine clinics. "
09/01/1986 - "These findings suggest that the ability of CCK-8 to maintain high bile flows during TPN may have prophylactic relevance for prevention of TPN-induced gallbladder disease. "
06/01/1985 - "The role of sincalide cholescintigraphy in the evaluation of patients with acalculus gallbladder disease."

01/01/1979 - " Conclusions reached by the conference participants were: 1) estrogens are more effective than placebos in reducing vasomotor symptoms associated with menopause; 2) therapy should be undertaken only if the patient considers the symptoms to be severe enough to warrant treatment, and the smallest dose possible should be administered; 3) estrogens are effective in treating atrophy of the vaginal epithelium, but the use of estrogen creams to treat localized vaginal areas needs further study; 4) estrogens should not be used to treat primary psychological problems; 5) insufficient data is available for determining whether estrogen therapy decreases the risk of fracture associated with osteoporosis; 6) recent investigations indicate estrogen therapy reduces bone loss, but it is not known if the effect is permanant; 7) estrogen therapy appears to neither increase nor decrease the risk of thromboembolism, stroke, or heart disease; 8) estrogen therapy is associated with an increased risk of endometrial cancer but primarily with low grade endometrial cancers; 9) cystic hyperplasia is associated with unopposed estrogen therapy; 10) yearly endometrial samples should be obtained and checked for endometrial changes for all patients receiving estrogen therapy; 11) evidence supporting an association between estrogen therapy and breast cancer is indecisive; and 12) estrogen therapy is associated with an increased risk of gallbladder disease. "

02/01/1999 - "The prostanoid response of gallbladder cells stimulated by proinflammatory agents is inhibited by COX-2 inhibitors suggesting that these agents may be effective in treating the pain and inflammation of gallbladder disease."

01/01/2023 - "Laparoscopic cholecystectomy (LC) is the gold standard for most benign gallbladder diseases. "
03/01/2009 - "Laparoscopic cholecystectomy is now indisputably the gold standard for managing most gallbladder diseases. "
09/01/2006 - "Laparoscopic cholecystectomy is the gold standard treatment for most gallbladder diseases. "
02/01/2003 - "Laparoscopic cholecystectomy (LC) is accepted as a "gold standard" for treating most gallbladder diseases because it is superior to the open method, causes less postoperative pulmonary dysfunction, and promotes earlier postoperative recovery. "
01/01/2023 - "Traditional laparoscopic cholecystectomy is the more cost-effective treatment modality for benign gallbladder disease. "

01/01/1991 - "Laparoscopic guided cholecystectomy appears to offer a number of advantages in patient care as well as a significant reduction in health care expenses for gallbladder disease. "
01/01/2019 - "Letter to Editor: Routine Pathology and Postoperative Follow-Up are Not Cost-Effective in Cholecystectomy for Benign Gallbladder Disease."
01/01/2019 - "Authors' Reply: Routine Pathology and Postoperative Follow-Up are not Cost-Effective in Cholecystectomy for Benign Gallbladder Disease."
01/01/2019 - "Correction to: Authors' Reply: Routine Pathology and Postoperative Follow-Up are not Cost-Effective in Cholecystectomy for Benign Gallbladder Disease."
10/01/2018 - "Routine Pathology and Postoperative Follow-Up are Not Cost-Effective in Cholecystectomy for Benign Gallbladder Disease."

01/01/2016 - "Surgery for metastatic gallbladder disease of renal origin seems to be a feasible therapy which is capable of increasing patients' overall survival."
05/02/2015 - "Replacement therapy with factor concentrates should be initiated at once, and early surgery for gallbladder disease should be considered. "
07/10/2008 - "The risk of gallbladder disease decreased with time since stopping therapy (trend P=0.004). "
05/01/2007 - "Gallbladder disease in the general population: association with cardiovascular morbidity and therapy."
01/01/2006 - "Is there a link between oestrogen therapy and gallbladder disease?"

04/01/1996 - "However, none of the patients needed a surgical procedure during the study because of gallbladder disease. "
01/01/2022 - "We aimed to generate a reliable report on 4 of the most common gallbladder surgical procedures in England to allow cross-procedure comparisons and highlight significant changes in the management of benign gallbladder disease over time. "
12/15/2019 - "Therefore, nSILC is a feasible surgical procedure for patients with benign gallbladder disease compared to TPLC and an effective approach to overcome the limitations of pSILC."
01/01/2019 - "Recognition of this anomaly and its various types is important since it can complicate a gallbladder disease or a simple hepatobiliary surgical procedure. "
02/01/1995 - "Readmissions within 10 months of the original surgery with another diagnosis similar to gallbladder disease were considered "missed pathology" at the original surgical procedure. "

05/01/2000 - "To examine the role of estrogen replacement therapy on the development of gallbladder disease in postmenopausal women. "
05/01/2000 - "Estrogen replacement therapy and gallbladder disease in postmenopausal women."
09/01/1981 - "Studies have shown that side effects of estrogen replacement therapy include endometrial cancer, hypertension, gallbladder disease, and angina pectoris. "
02/01/1983 - " Complications of estrogen replacement include endometrial cancer, breast cancer, hypertension, hyperlipidemia, and gallbladder disease, the latter 3 apparently resulting from hepatic action of estrogen replacement therapy. "
04/01/1977 - "Contraindications to estrogen replacement include undiagnosed vaginal bleeding, breast cancer history of thromboembolic disease, liver disease, uterine leiomyomata, hypertension, diabetes, migraine headaches or gall bladder disease. "